ILC Therapeutics Raises £3.5M in Pre-IPO Funding
- ILC Therapeutics, a Glasgow, Scotland-based biotechnology company, raised £3.5M in Pre-IPO funding
- The round was led by Robert Kopple with participation from Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management
- ILCTherapeutics is a biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates
- The company intends to use the funds to accelerate development of Alfacyte – its lead hybrid interferon designed to combat viral infections including Covid
- Alfacyte™ is ILCT’s lead Hybrid interferon drug candidate and is being developed as an inhaled medicine to treat Respiratory Viral Infections
- The company was founded by Prof. W. H. Stimson FRSE, who established the Department of Immunology at The University of Strathclyde
